DailyIQ
Last updated18 minutes ago

EXEL·Exelixis Inc.

$58.43
+0.10 (+0.17%)
Overnight$58.26-0.17 (-0.29%)
High
$59.27
Open
$58.47
Market Cap
14.57B
52W High
$61.14
Low
$57.50
P. Close
$58.43
P/E
16.93
52W Low
$33.76
Fwd P/E
13.96
DailyIQ Est.
$55.18
Inst. Ownership
0.1%
Short Interest
10.56%
Days to Cover
12.4
Technical Score (1D)
73
BULLISH
News Sentiment
64
BULLISH
On Oct 7, Exelixis completed $1.1 billion of share repurchases in 2025, reducing its shares outstanding by 21 % over three years. The buyback program lowered the average repurchase price to $47.85 per share, below the market price of $58.33, thereby increasing the value of each remaining share. As a result, earnings per share growth accelerated to 84.1 % annually, outpacing net income growth of 73.7 %. The company’s strong cash flow base has supported the buyback program and positioned Exelixis for continued upside. The actions reported on Oct 7 highlighted how the share repurchases have added roughly ten percentage points to EPS growth each year.
LOW TARGET
$41 -29.8%
2 analysts
MEAN TARGET
$54 -6.9%
18 analysts
HIGH TARGET
$70 +19.8%
8 analysts
PRICE RANGE
$41.00 - $70.00
SB / B / H / S / SS
4/8/14/1/1
DAILYIQ EST.
$55.18 (-5.6%)
Bought (1Y)
0 shares
$0
Sold (1Y)
67,000 shares
$3.4M
Beckerle Mary C-
Sell9,812 shares2026-08-10
Eckhardt Sue Gail-
Sell9,812 shares2026-06-01
WYSZOMIERSKI JACK L-
Sell3,925 shares2026-06-01
JOHNSON DAVID EDWARD-
Award/Grant19,133 shares2026-05-27
POSTE GEORGE-
Award/Grant8,367 shares2026-05-27
76/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
96.4%
Net Margin
33.7%
Revenue CAGR
19.9%
Current Ratio
3.56x
Debt / Equity
0.09x
Return on Equity
36.2%

EPS

EstBeatMiss
$0.64$0.71$0.78$0.86$0.93Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.90 - -
Q3'25$0.67$0.78+16.2%

Revenue

EstBeatMiss
$588M$609M$630M$651M$671MQ3'25Q3'26
QtrEstActual+/−
Q3'26$662M - -
Q3'25 - $598M -

Market Data

EXEL Stock Snapshot

BULLISH73/100
$58.26−$0.17 (0.3%)
Market cap
14.57B
P/E ratio
16.9
Day range
$57.50 – $59.27
News sentiment
64/100 · Bullish
Analyst target
$54.40 (-6.6%)
Consensus
Hold · 28 analysts
52-week range+72.6% off low · -4.7% from high
$33.76$61.14
Price $58.26 DailyIQ Est. $55.18

Exelixis Inc. screens well technically, with price sitting near its 52-week high. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What EXEL's own history says about today's numbers

Realized volatility (21d)
27.1% 11th pct
Below its peak
-0.4%
vs 200-day average
+19.9%
Up days (1y)
52%

Exelixis Inc. is currently running 27.1% annualised volatility over the last 21 sessions. Measured against EXEL's own 13 years of daily returns rather than a market-wide average, that is the 11th percentile — unusually subdued by its own history, against a typical reading of 43.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

EXEL is at its running peak. Across 12 full years on file its median worst-drawdown-in-a-year was -34.6%, with the deepest at -84.4% in 2014 — so highs have historically been given back before they were extended.

Price sits +19.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 73rd percentile — a somewhat wider gap than its own norm. Over the past year EXEL closed higher on 52% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, EXEL finished the month higher 5 of 13 times, with a median return of -6.8% and an average of -3.5%. Its strongest month historically has been November at +7.3% on average, its weakest March at -4.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: EXEL has opened more than 2% away from the prior close in 387 of 3,267 sessions (11.8% of the time), with the largest gaps running +40.7% and -27.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against EXEL's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of EXEL's sector?

Exelixis Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, EXEL ranks 10th of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
64
Industry rank
#10 of 15

Options Market

What is the options market pricing for EXEL?

CallsPuts

For Exelixis Inc.'s nearest expiry (2026-10-16, 8 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 3.17), with at-the-money implied volatility around 46.3%. The options market is pricing roughly a ±10.3% move by that expiry — a range of about $51.63–$63.54.

Put/call ratio (2026-10-16)
3.17
ATM implied volatility
46.3%
Total open interest
18,825
Expected move by 2026-10-16
±10.3% ($51.63–$63.54)

Analyst Rating Changes

Are analysts turning bullish or bearish on EXEL?

BMO Capital most recently initiated coverage on Exelixis Inc. to Market Perform on Aug 19, 2026 with a price target of $54. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
BMO Capital — Market Perform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 19, 2026BMO CapitalInitiatedMarket Perform$54
Aug 6, 2026Truist SecuritiesMaintainedHold$56 → $52
Aug 6, 2026StifelMaintainedHold$47 → $51
Jul 23, 2026Morgan StanleyMaintainedEqual-Weight$50 → $53
Jul 14, 2026BarclaysMaintainedEqual-Weight$45 → $49
Jul 13, 2026Wells FargoMaintainedEqual-Weight$40 → $49
Jul 7, 2026RBC CapitalMaintainedSector Perform$43 → $46
Jul 7, 2026Truist SecuritiesMaintainedHold$54 → $56
Jul 2, 2026UBSMaintainedNeutral$43 → $52
Jul 2, 2026HC Wainwright & Co.ReiteratedBuy$56
Jun 25, 2026Truist SecuritiesDowngradeBuy → Hold$51 → $54
Jun 24, 2026CitizensMaintainedMarket Outperform$50 → $55

News Sentiment Analysis

Sentiment gathered from recent headlines

64/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Exelixis (EXEL) has posted a 172.4% total return over five years, prompting analysts to evaluate whether current earnings can justify the stock’s valuation. The company’s oncology portfolio is expected to generate recurring earnings and cash flows, which could support a higher price relative to a Fair Ratio benchmark. Investors are weighing whether the earnings profile aligns with the stock’s recent performance and whether it warrants a revaluation.
What did this article say?
Exelixis (EXEL) completed $1.1 billion of share repurchases in 2025, cutting shares outstanding by 21% over three years and boosting earnings per share growth to 84.1% annually versus 73.7% net income growth. The company’s buyback program has added roughly ten percentage points to EPS growth each year, while the average repurchase price of $47.85 per share remained below the market price of $58.33. These actions have increased the value of each remaining share and positioned EXEL for continued upside as it maintains a strong cash flow base.
What did this article say?
ChartMill identified EXELIXIS as a strong technical candidate, awarding it a 10/10 technical score and an 8/10 setup rating. The stock sits within a tight base, suggesting a clear entry point for traders. The analysis highlights a defined breakout potential but does not indicate any fundamental catalyst or earnings impact. The technical assessment alone implies a modest positive outlook for short‑term price action.
What did this article say?
Exelixis reported a 10% year‑over‑year increase in quarterly revenue, driven by its flagship cabozantinib product, CABOMETYX, which generated $573 million of the $629 million total. GAAP net income rose to $212 million, and the company maintained a $1.4 billion cash balance while repurchasing $312 million of shares. Institutional investors increased buying activity, reflecting confidence in the company’s growth trajectory. The combined financial performance and investor demand contributed to a 34% share price gain year‑to‑date.
What did this article say?
Exelixis (EXEL) announced that the FDA has granted an extension to review its zanzalintinib plus atezolizumab combination for metastatic colorectal cancer. The extension follows a major amendment submitted by the company, incorporating updated safety and efficacy data. While the delay postpones a definitive decision, the additional data may strengthen the application and improve the likelihood of eventual approval. The extension signals regulatory interest but also introduces uncertainty regarding the timeline for market entry.
What did this article say?
Exelixis (EXEL) received a three‑month extension from the FDA for its zanzalintinib/atezolizumab combination, pushing the target action date to March 3, 2027. The extension follows a request for additional safety and efficacy data, indicating the agency is not yet convinced the benefit‑risk profile is favorable. The company’s key evidence remains the overall‑survival benefit in the STELLAR‑303 Phase 3 trial, but the extension suggests the data package may be insufficient for a timely approval. This delay could postpone market entry and revenue recognition for the colorectal cancer indication.
What did this article say?
Exelixis, Inc. (EXEL) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, outlining its current pipeline and strategic priorities. The company’s CEO, Michael Morrissey, emphasized ongoing clinical development of its lead oncology candidates and discussed potential regulatory milestones. No new financial guidance or material corporate actions were disclosed, and the presentation focused on status updates rather than earnings or acquisitions. The remarks suggest a steady progression of the pipeline without immediate upside or downside catalysts for the near term.

Technical Analysis

Real-time indicators across multiple timeframes

73
BULLISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $12.17M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold223,7240.09%$12.17M2026-09-02
Q2 2026 flow:223.7K sh bought ($12.17M)0 sh sold ($0)net +223.7K sh (+$12.17M)